TEM - Tempus AI, Inc.
As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data, specialized models, and integration into diagnostic workflows.
Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung c
TEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.
Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several biomarkers, supporting its potential to identify patients who may need confirmatory biomarker testing. Results from the study were presented at the European Society for Med.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026. The company will host a conference call and live audio webcast at 8:45 a.m ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financ.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext™ and GenomeReveal™, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases. Many patients and families undergo years of testing without a diagnosis, and even comprehensive genetic testing can miss or be unable to interpret disease-causin.
TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.
TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock, but premium valuation and reimbursement risks warrant caution.
Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.
Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a
CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know.
TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year's congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, non-small cell lung cancer (NSCLC), renal cell carcinoma and gynecologic mali.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR). MR is a common form of heart valve disease where blood leaks backward through the mitral valve. Because early stages are often asymptomatic or manifest as no.
Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the business's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total value of $19,367,500.00. Following the sale, the chief executive officer directly owned 100,000 shares of
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
The transaction involved 7,062 shares with an estimated value of $529,650 as of the transaction date. The traded shares represented ~10% of the equity stake held before the filing.